Innoviva (INVA) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings or view top-rated stocks.

3 analysts have issued 12 month price objectives for Innoviva's shares. Their INVA share price forecasts range from $10.00 to $22.50. On average, they expect the company's share price to reach $15.17 in the next year. This suggests a possible upside of 14.7% from the stock's current price.
View analysts price targets for INVA or view top-rated stocks among Wall Street analysts.

Innoviva's stock was trading at $13.25 at the beginning of 2023. Since then, INVA stock has decreased by 0.2% and is now trading at $13.22.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our INVA earnings forecast.

Innoviva, Inc. (NASDAQ:INVA) issued its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported $0.08 earnings per share for the quarter. The biotechnology company earned $80.99 million during the quarter. Innoviva had a net margin of 80.35% and a trailing twelve-month return on equity of 19.28%.

ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares U.S. Pharmaceuticals ETF (IHE).Harbor Health Care ETF (MEDI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva's stock is owned by many different retail and institutional investors. Top institutional shareholders include Shaolin Capital Management LLC (0.00%), Dimensional Fund Advisors LP (5.99%), Renaissance Technologies LLC (5.52%), State Street Corp (3.66%), Geode Capital Management LLC (1.81%) and Pacer Advisors Inc. (1.35%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends.

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INVA stock can currently be purchased for approximately $13.22.

Innoviva (NASDAQ:INVA) has a market capitalization of $860.62 million and generates $331.34 million in revenue each year. The biotechnology company earns $213.92 million in net income (profit) each year or $2.26 on an earnings per share basis.

The company employs 101 workers across the globe.

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.